2025 Hyper Recent •CC0 1.0 Universal

This work is dedicated to the public domain. No rights reserved.

Access Preprint From Server
June 2nd, 2025
Version: 3
University of Oxford
cancer biology
biorxiv

IRE1 activity regulates tumour and microenvironment cell lineage states while stratifying localised and metastatic prostate cancer.

Doultsinos, D.Open in Google Scholar•Tomljanovic, I.Open in Google Scholar•Pilalis, E.Open in Google Scholar•Abusamra, S.Open in Google Scholar•Parmentier, R.Open in Google Scholar•Bridges, I. E.Open in Google Scholar•Figiel, S.Open in Google Scholar•Zekri, Y.Open in Google Scholar•Hester, J.Open in Google Scholar•Leach, D.Open in Google Scholaret al.

Prostate cancer (PCa) is an androgen receptor (AR) driven, high-incidence disease significantly contributing to cancer mortality. PCa is in need of better risk stratification at diagnosis and treatment outcomes in patients at high risk of metastasis. The unfolded protein response (UPR) is an AR-dependent process. However, the impact of the UPR transducer IRE1 on AR-dependent biology and treatment resistance has not been defined. We use diverse pre-clinical models of stress response to describe IRE1 activity impact on multiple disease stages and demonstrate its involvement with poor prognosis (RB1 loss), and cell lineage determination (club phenotypes). Integrating clinical transcriptomic datasets, we chart IRE1 activity throughout PCa evolution by developing a PCa-specific, IRE1 activity gene set (IRE1_18) reflecting both tumoral and micro-environmental niches. IRE1_18 can determine tumoral identity, inform androgen deprivation treatment suitability, prognosticate localised and metastatic disease independently from AR activity, and guide IRE1 modulation as a novel combination therapeutic.

Similar Papers

biorxiv
Wed Jun 04 2025
Isoform-Specific Gene Regulation by Progesterone Receptors Drives Divergent Phenotypes in Breast Cancer Cells
Exposure to progesterone is a recognized risk factor for breast cancer, and PGR polymorphisms are associated with various malignancies. Two progesterone receptor (PR) isoforms, full length PR-B and truncated PR-A, are expressed from the PGR gene in breast tissue and play crucial roles in normal physiology and breast cancer progression. An imbalance in the expression ratio of these isoforms, favori...
Gillis, N. E.
•
Truong, T. H.
•
Diep, C. H.
•
Spartz, A.
...•
Lange, C. A.
biorxiv
Wed Jun 04 2025
Molecular Phenotypic Plasticity Informs Possible Adaptive Change of Triple-Negative Breast Cancer Cells In Vivo
Background and Objectives: Cancer evolves via interconnected mechanisms, including changes in extrachromosomal DNA (ecDNA), genetic instability, and interactions with the tumor microenvironment (TME). These mechanisms allow for some clones to evolve metastatic traits, evade the immune system, and resist chemotherapy. However, how cancer cells evolve in vivo remains poorly understood. This study in...
Iftehimul, M.
•
Muganda, P. M.
•
Newman, R. H.
•
Rorie, C. J.
...•
Saha, D.
biorxiv
Wed Jun 04 2025
Loss of UFMylation supports prostate cancer metastasis and rewires cell metabolism towards hexosamine biosynthesis
The acquisition of metastatic features in tumor cells encompasses genetic and non-genetic adaptation, including reprogramming of cellular metabolism. Here we show that loss of UFMylation reroutes glucose metabolism, promotes invasive capacity and supports prostate cancer metastasis. Through transcriptome-based bioinformatics analysis, we identified a reduction in the ubiquitin-like modifier UFM1 a...
Bozal Basterra, L.
•
Salazar Palacio, M. C.
•
Ferreira Campos, A. M.
•
Demicco, M.
...•
Carracedo, A.
biorxiv
Tue Jun 03 2025
Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors
For all drugs, effective target engagement requires sufficient intracellular concentrations of drug to be reached, but whether tumour heterogeneity impacts drug distribution and efficacy is poorly studied. PARP inhibitors have transformed treatment of high-grade serous ovarian carcinoma (HGSOC), but resistance remains a clinical hurdle in this highly heterogeneous tumour type. We developed a patie...
Moncayo, C. R.
•
Restuadi, R.
•
Zhang, G.
•
Marks, D.
...•
Fets, L.
biorxiv
Tue Jun 03 2025
In Search of the Perfect Model: How Cancer Cell Lines Relate to Native Cancers
Cancer cell lines are frequently used in biological and translational research to study cellular mechanisms and explore treatment options. However, cancer cell lines may display mutational profiles divergent from native cancers or may be misidentified or contaminated. We explored how similar cancer cell lines are to native cancers to find the most suitable representations for the corresponding dis...
Paloots, R.
•
Yang, Z.
•
Baudis, M.
biorxiv
Tue Jun 03 2025
Targeting HMGA1-driven leukemic transformation in myeloproliferative neoplasms with pacritinib
Progression of myeloproliferative neoplasms (MPNs) to secondary acute myeloid leukemia (sAML) is a lethal transition lacking reliable early biomarkers and effective therapies. Integrating multi-omics analyses, a cohort of 240 patient biopsies, and functional studies, we identify High Mobility Group A1 (HMGA1) as a critical driver and predictor of this transformation. HMGA1 expression, readily dete...
Yang, C.
•
Li, Y.
•
Chen, K.
•
Tang, X.
...•
Wu, Z.
biorxiv
Tue Jun 03 2025
The mutational landscape defines the proteome and spatial organization of tumor, stroma and immune cells in ovarian cancer
High-grade serous ovarian cancer (HGSOC) is a highly aggressive and lethal form of ovarian cancer. Challenges to diagnosis and treatment include a lack of effective screening methods for early detection, the absence of cancer-specific symptoms, and the development of chemoresistance. The genomic instability of HGSOC, further complicated by homologous recombination deficiency (HRD), leads to hetero...
Dabke, K.
•
Gull, N.
•
Kreimer, S.
•
Peng, P.-C.
...•
Jones, M. R.
biorxiv
Tue Jun 03 2025
A missense mutation in Muc2 promotes gut microbiome- and metabolome-dependent colitis-associated tumorigenesis.
Colitis-associated cancer (CAC) arises from a complex interplay between host and environmental factors, including the gut microbiome. Since ulcerative colitis (UC), a significant risk factor for CAC, is rising in prevalence worldwide, an integrative approach is essential to identify potential triggers linking inflammation to cancer. In the present study, we investigated the role of the gut microbi...
Verna, G.
•
De Santis, S.
•
Islam, B.
•
Sommella, E. M.
...•
Cominelli, F.
biorxiv
Tue Jun 03 2025
GAN-Enhanced Machine Learning and Metabolic Modeling Identify Reprogramming in Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest forms of cancer and presents a significant clinical challenge due to poor prognosis and limited treatment options. In this study, we developed a novel framework integrating genome-scale metabolic modeling (GSM) with machine learning to identify metabolic biomarkers and vulnerabilities in PDAC. We addressed the inherent class imbalance...
Razmpour, T.
•
Tabibian, M.
•
Roohi, A.
•
Saha, R.
biorxiv
Tue Jun 03 2025
Mutation profiling of KRAS and BRAF in primary tumors and circulating tumor cells of colorectal cancer patients using PNA-LNA molecular switch
Identifying KRAS and BRAF mutation status is essential for guiding targeted therapies and enhancing treatment outcomes in colorectal cancer (CRC). This study employs the PNA-LNA molecular switch to detect mutations in KRAS codon 12 (c.35G>T/G12V) and BRAF codon 600 (c.1799T>A/V600E) from primary tumours and circulating tumour cells (CTCs) in CRC patients, correlating mutation status with clinicopa...
Islam, M. S.
•
Ranjit, E.
•
Aktar, S.
•
Moetamedirad, N.
...•
Lam, A. K.